10x Genomics
TXG
$14.00
Share price
-4.37%
Change (1 day)
-31.07%
Change (1 year)
Categories
10x Genomics (TXG) - Cash on Hand
Cash on Hand as of March 2025 : $0.42 Billion USD
According to 10x Genomics
's latest financial reports the company has $0.42 Billion USD in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
10x Genomics - Cash on Hand chart (from 2018 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | $0.39 B | 1.21% |
| 2023-12-31 | $0.38 B | -9.6% |
| 2022-12-31 | $0.42 B | -26.8% |
| 2021-12-31 | $0.58 B | -11.48% |
| 2020-12-31 | $0.66 B | 56.45% |
| 2019-12-31 | $0.42 B | 551.76% |
| 2018-12-31 | $65.08 M | 35.99% |
| 2017-12-31 | $47.85 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novocure
NVCR | $0.92 B | 117.64% | Jersey |
 Novavax NVAX | $0.73 B | 71.34% | 🇺🇸 USA |
 Organovo ONVO | $11.31 M | -97.35% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | $0.12 B | -70.62% | 🇬🇧 UK |